{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T09:08:16Z","timestamp":1771751296507,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Body composition (BC) analysis is performed to quantify the relative amounts of different body tissues as a measure of physical fitness and tumor cachexia. We hypothesized that relative changes in body composition (BC) parameters, assessed by an artificial intelligence\u2013based, PACS-integrated software, between baseline imaging before the start of radioligand therapy (RLT) and interim staging after two RLT cycles could predict overall survival (OS) in patients with metastatic castration-resistant prostate cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a single-center, retrospective analysis of 92 patients with mCRPC undergoing [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA RLT between September 2015 and December 2023. All patients had [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-PSMA-11 PET\/CT at baseline (\u2264\u20096\u00a0weeks before the first RLT cycle) and at interim staging (6\u20138\u00a0weeks after the second RLT cycle) allowing for longitudinal BC assessment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>During follow-up, 78 patients (85%) died. Median OS was 16.3\u00a0months. Median follow-up time in survivors was 25.6\u00a0months. The 1\u00a0year mortality rate was 32.6% (95%CI 23.0\u201342.2%) and the 5\u00a0year mortality rate was 92.9% (95%CI 85.8\u2013100.0%). In multivariable regression, relative change in visceral adipose tissue (VAT) (HR: 0.26; <jats:italic>p<\/jats:italic>\u2009=\u20090.006), previous chemotherapy of any type (HR: 2.4; <jats:italic>p<\/jats:italic>\u2009=\u20090.003), the presence of liver metastases (HR: 2.4; <jats:italic>p<\/jats:italic>\u2009=\u20090.018) and a higher baseline De Ritis ratio (HR: 1.4; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) remained independent predictors of OS. Patients with a higher decrease in VAT (&lt;\u2009\u221220%) had a median OS of 10.2\u00a0months versus 18.5\u00a0months in patients with a lower VAT decrease or VAT increase (\u2265\u2009\u221220%) (log-rank test: <jats:italic>p<\/jats:italic>\u2009=\u20090.008). In a separate Cox model, the change in VAT predicted OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.005) independent of the best PSA response after 1\u20132 RLT cycles (<jats:italic>p<\/jats:italic>\u2009=\u20090.09), and there was no interaction between the two (<jats:italic>p<\/jats:italic>\u2009=\u20090.09).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>PACS-Integrated, AI-based BC monitoring detects relative changes in the VAT, Which was an independent predictor of shorter OS in our population of patients undergoing RLT<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13550-025-01312-9","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:53:46Z","timestamp":1756403626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-5704","authenticated-orcid":false,"given":"Tristan","family":"Ruhwedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Rogasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Galler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imke","family":"Schatka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Biernath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyd","family":"Shnayien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Kolck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Geisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick Lasse","family":"Beetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"1312_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","volume":"17","author":"C Verry","year":"2022","unstructured":"Verry C, Vincendeau S, Massetti M, Blachier M, Vimont A, Bazil ML, et al. Pattern of clinical progression until metastatic castration-resistant prostate cancer: an epidemiological study from the European Prostate Cancer Registry. Target Oncol. 2022;17:441\u201351. https:\/\/doi.org\/10.1007\/s11523-022-00899-6.","journal-title":"Target Oncol"},{"key":"1312_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275\u201385. https:\/\/doi.org\/10.2214\/AJR.18.20845.","journal-title":"AJR Am J Roentgenol"},{"key":"1312_CR7","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","volume":"48","author":"R Manafi-Farid","year":"2021","unstructured":"Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48:4028\u201341. https:\/\/doi.org\/10.1007\/s00259-021-05237-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1312_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204907","author":"S Gaal","year":"2023","unstructured":"Gaal S, Huang K, Rogasch JMM, Jochens HV, De Santis M, Erber B, et al. Prognostic value of the de Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [(177)Lu]Lu-PSMA-617 radioligand therapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15204907.","journal-title":"Cancers (Basel)"},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","volume":"17","author":"L Emmett","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17:15\u201322. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.014.","journal-title":"Clin Genitourin Cancer"},{"key":"1312_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.123.266702","volume":"65","author":"PE Hartrampf","year":"2024","unstructured":"Hartrampf PE, Huttmann T, Seitz AK, Kubler H, Serfling SE, Higuchi T, et al. Prognostic performance of RECIP 1.0 based on [(18)F]PSMA-1007 PET in prostate cancer patients treated with [(177)Lu]Lu-PSMA I&T. J Nucl Med. 2024;65:560\u20135. https:\/\/doi.org\/10.2967\/jnumed.123.266702.","journal-title":"J Nucl Med"},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"},{"key":"1312_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tipsro.2020.10.001","volume":"16","author":"M Anjanappa","year":"2020","unstructured":"Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, et al. Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020;16:50\u20137. https:\/\/doi.org\/10.1016\/j.tipsro.2020.10.001.","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"e0215915","DOI":"10.1371\/journal.pone.0215915","volume":"14","author":"ES Gruber","year":"2019","unstructured":"Gruber ES, Jomrich G, Tamandl D, Gnant M, Schindl M, Sahora K. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. PLoS ONE. 2019;14:e0215915. https:\/\/doi.org\/10.1371\/journal.pone.0215915.","journal-title":"PLoS ONE"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/SLA.0000000000002679","volume":"268","author":"C Simonsen","year":"2018","unstructured":"Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology: a meta-analysis. Ann Surg. 2018;268:58\u201369. https:\/\/doi.org\/10.1097\/SLA.0000000000002679.","journal-title":"Ann Surg"},{"key":"1312_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1017\/S0029665115004279","volume":"75","author":"CM Prado","year":"2016","unstructured":"Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75:188\u201398. https:\/\/doi.org\/10.1017\/S0029665115004279.","journal-title":"Proc Nutr Soc"},{"key":"1312_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/jcsm.12731","volume":"12","author":"NL Beetz","year":"2021","unstructured":"Beetz NL, Maier C, Shnayien S, Trippel TD, Gehle P, Fehrenbach U, et al. Artificial intelligence-based analysis of body composition in Marfan: skeletal muscle density and psoas muscle index predict aortic enlargement. J Cachexia Sarcopenia Muscle. 2021;12:993\u20139. https:\/\/doi.org\/10.1002\/jcsm.12731.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1312_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122921","author":"U Fehrenbach","year":"2021","unstructured":"Fehrenbach U, Wuensch T, Gabriel P, Segger L, Yamaguchi T, Auer TA, et al. CT body composition of sarcopenia and sarcopenic obesity: predictors of postoperative complications and survival in patients with locally advanced esophageal adenocarcinoma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13122921.","journal-title":"Cancers (Basel)"},{"key":"1312_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092356","author":"NL Beetz","year":"2022","unstructured":"Beetz NL, Geisel D, Maier C, Auer TA, Shnayien S, Malinka T, et al. Influence of baseline CT body composition parameters on survival in patients with pancreatic adenocarcinoma. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11092356.","journal-title":"J Clin Med"},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/ejcts\/ezy244","volume":"55","author":"M Kofler","year":"2019","unstructured":"Kofler M, Reinstadler SJ, Mayr A, Stastny L, Reindl M, Dumfarth J, et al. Prognostic implications of psoas muscle area in patients undergoing transcatheter aortic valve implantation. Eur J Cardiothorac Surg. 2019;55:210\u20136. https:\/\/doi.org\/10.1093\/ejcts\/ezy244.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1312_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13613-023-01162-5","volume":"13","author":"J Kolck","year":"2023","unstructured":"Kolck J, Rako ZA, Beetz NL, Auer TA, Segger LK, Pille C, et al. Intermittent body composition analysis as monitoring tool for muscle wasting in critically ill COVID-19 patients. Ann Intensive Care. 2023;13:61. https:\/\/doi.org\/10.1186\/s13613-023-01162-5.","journal-title":"Ann Intensive Care"},{"key":"1312_CR21","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2967\/jnumed.122.265379","volume":"64","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, Mihatsch PW, Seitz AK, Solnes LB, Rowe SP, Pomper MG, et al. Elevated body mass index is associated with improved overall survival in castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen-directed radioligand therapy. J Nucl Med. 2023;64:1272\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.265379.","journal-title":"J Nucl Med"},{"key":"1312_CR22","first-page":"471","volume":"48","author":"S Surti","year":"2007","unstructured":"Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET\/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007;48:471\u201380.","journal-title":"J Nucl Med"},{"key":"1312_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-019-0244-0","volume":"6","author":"D Vandendriessche","year":"2019","unstructured":"Vandendriessche D, Uribe J, Bertin H, De Geeter F. Performance characteristics of silicon photomultiplier based 15-cm AFOV TOF PET\/CT. EJNMMI Phys. 2019;6:8. https:\/\/doi.org\/10.1186\/s40658-019-0244-0.","journal-title":"EJNMMI Phys"},{"key":"1312_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/crt2.44","volume":"7","author":"NL Beetz","year":"2022","unstructured":"Beetz NL, Maier C, Segger L, Shnayien S, Trippel TD, Lindow N, et al. First PACS-integrated artificial intelligence-based software tool for rapid and fully automatic analysis of body composition from CT in clinical routine. JCSM Clin Rep. 2022;7:3\u201311. https:\/\/doi.org\/10.1002\/crt2.44.","journal-title":"JCSM Clin Rep"},{"key":"1312_CR25","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7:e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862.","journal-title":"PLoS ONE"},{"key":"1312_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41391-019-0186-6","volume":"23","author":"J Stangl-Kremser","year":"2020","unstructured":"Stangl-Kremser J, Suarez-Ibarrola R, Andrea D, Korn SM, Pones M, Kramer G, et al. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. Prostate Cancer Prostatic Dis. 2020;23:309\u201315. https:\/\/doi.org\/10.1038\/s41391-019-0186-6.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1312_CR27","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX, Buck AK, Rowe SP, Higuchi T, Seitz AK, et al. Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3269\u201376. https:\/\/doi.org\/10.1007\/s00259-022-05744-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1312_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/jhn.12861","volume":"34","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Z, Jiang L, Xue Z, Ma Z, Kang W, et al. Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: a retrospective cohort study. J Hum Nutr Diet. 2021;34:585\u201394. https:\/\/doi.org\/10.1111\/jhn.12861.","journal-title":"J Hum Nutr Diet"},{"key":"1312_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3346\/jkms.2016.31.10.1571","volume":"31","author":"EK Choe","year":"2016","unstructured":"Choe EK, Park KJ, Ryoo SB, Moon SH, Oh HK, Han EC. Prognostic impact of changes in adipose tissue areas after colectomy in colorectal cancer patients. J Korean Med Sci. 2016;31:1571\u20138. https:\/\/doi.org\/10.3346\/jkms.2016.31.10.1571.","journal-title":"J Korean Med Sci"},{"key":"1312_CR30","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1002\/cam4.3964","volume":"10","author":"O Nakano","year":"2021","unstructured":"Nakano O, Kawai H, Kobayashi T, Kohisa J, Ikarashi S, Hayashi K, et al. Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer. Cancer Med. 2021;10:4291\u2013301. https:\/\/doi.org\/10.1002\/cam4.3964.","journal-title":"Cancer Med"},{"key":"1312_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168491","author":"H Nishikawa","year":"2021","unstructured":"Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Cancer cachexia: its mechanism and clinical significance. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22168491.","journal-title":"Int J Mol Sci"},{"key":"1312_CR32","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597\u2013605. https:\/\/doi.org\/10.2147\/CMAR.S261585.","journal-title":"Cancer Manag Res"},{"key":"1312_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2967\/jnumed.121.262543","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, et al. Safety of PSMA-targeted molecular radioligand therapy with (177)Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC (NCT03042312). J Nucl Med. 2021;62:1447\u201356. https:\/\/doi.org\/10.2967\/jnumed.121.262543.","journal-title":"J Nucl Med"},{"key":"1312_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/crt2.61","volume":"8","author":"J Kolck","year":"2023","unstructured":"Kolck J, Sch\u00e4fer FM, Labbus K, Wittenberg S, Hosse C, Auer TA, et al. Predictive influence of artificial intelligence-based body composition analysis in trauma patients with pelvic injuries. JCSM Clin Rep. 2023;8:49\u201357. https:\/\/doi.org\/10.1002\/crt2.61.","journal-title":"JCSM Clin Rep"},{"key":"1312_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_350946","volume":"42","author":"A Gafita","year":"2022","unstructured":"Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book. 2022;42:1\u201317. https:\/\/doi.org\/10.1200\/EDBK_350946.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1312_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/cancers14010149","volume":"14","author":"F Kind","year":"2021","unstructured":"Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA change after [(177)Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival. Cancers (Basel). 2021;14:149. https:\/\/doi.org\/10.3390\/cancers14010149.","journal-title":"Cancers (Basel)"},{"key":"1312_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14014","volume":"53","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K. Prognostic role of early prostate specific antigen changes after [(177) Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: a meta-analysis. Eur J Clin Invest. 2023;53: e14014. https:\/\/doi.org\/10.1111\/eci.14014.","journal-title":"Eur J Clin Invest"},{"key":"1312_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"M Kafka","year":"2024","unstructured":"Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, et al. Real-world outcomes and predictive biomarkers for (177)lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant prostate cancer: a European Association of Urology Young Academic Urologists Prostate Cancer Working Group multi-institutional observational study. Eur Urol Oncol. 2024;7:421\u20139. https:\/\/doi.org\/10.1016\/j.euo.2023.07.018.","journal-title":"Eur Urol Oncol"},{"key":"1312_CR39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.118.216820","volume":"60","author":"TW Barber","year":"2019","unstructured":"Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955\u201362. https:\/\/doi.org\/10.2967\/jnumed.118.216820.","journal-title":"J Nucl Med"},{"key":"1312_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113\u201322. https:\/\/doi.org\/10.1007\/s00259-020-04797-9.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01312-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:53:48Z","timestamp":1756403628000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01312-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01312-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (reference ID: EA4\/152\/20). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I.S. is serving as a Guest Editor for EJNMMI Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}